Jeannette Crisostomo

Benchmark Research (United States) — United States

Medicine · Health Sciences

5h-index268citations21works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Immunotherapy and Immune Responses(8), Immune Cell Function and Interaction(5), Biosimilars and Bioanalytical Methods(5), Cancer Immunotherapy and Biomarkers(4)

Publications21 total

Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD+ aml Patients
Blood·2022· 1 cited
685 Preliminary results of MT-401 in post-transplant MRD<sup>+</sup> AML patients
Regular and Young Investigator Award Abstracts·2022Open Access
AML-109 Preliminary Results of MT-401 in Post-Transplant Measurable Residual Disease Positive (MRD+) Acute Myeloid Leukemia (AML) Patients
Clinical Lymphoma Myeloma & Leukemia·2022
Poster: AML-109 Preliminary Results of MT-401 in Post-Transplant Measurable Residual Disease Positive (MRD+) Acute Myeloid Leukemia (AML) Patients
Clinical Lymphoma Myeloma & Leukemia·2022
Robotic automation of t cell generation for the treatment of acute myeloid leukemia (AML)
Cytotherapy·2021
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Leukemia·2019· 78 citedOpen Access
MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9
Blood·2017
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
Molecular Therapy·2017· 103 citedOpen Access
Abstract 3745: Dual-switch TCR: A two-ligand system to control PRAME TCR-modified T cell proliferation and death using inducible MyD88/CD40 and caspase-9
Cancer Research·2017
Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma
Blood·2016· 4 cited
Abstract B078: GoTCR: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in myeloma
Cancer Immunology Research·2016
Abstract LB-084: Go-TCR™: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells, increasing anti-tumor efficacy
Cancer Research·2016
Efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch.
Journal of Clinical Oncology·2016· 1 cited
746. Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy
Molecular Therapy·2016· 1 citedOpen Access
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
Journal of Clinical Oncology·2016· 2 cited
Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma
Blood·2015· 1 cited
Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9
Blood·2015
MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells.
Journal of Clinical Oncology·2015· 3 cited
Genetic Deletion of Mst1 Alters T Cell Function and Protects against Autoimmunity
PLoS ONE·2014· 47 citedOpen Access
Integrin-α FG-GAP Repeat-Containing Protein 2 Is Critical for Normal B Cell Differentiation and Controls Disease Development in a Lupus Model
The Journal of Immunology·2013· 13 cited
page 1 of 2Next →

Frequent Co-authors

Aaron E. Foster(13), David M. Spencer(13), An Lu(11), Kevin M. Slawin(11), Aruna Mahendravada(7), Mariam Khalil(6), David Torres(6), Tania Véliz Rodríguez(6), Mirjam H.M. Heemskerk(6), Nicholas Shinners(4), Sunandan Saha(4), Tsvetelina Pentcheva‐Hoang(4), Annemarie Moseley(4), Lorenz Jahn(4), Peter S. Chang(4), Pei‐Yi Lin(4), Mythili Koneru(4), Shukaib Arslan(4), Hongtao Liu(4), Nelli Bejanyan(4)